Comparative Cerebroprotective Potential of d- and l-Carnosine Following Ischemic Stroke in Mice
Authors:
- Saurabh JainSJSaurabh Jain
- Eun-Sun KimEKEun-Sun Kim
- Donghyun KimDKDonghyun Kim
- David BurrowsDBDavid Burrows
- Milena De FeliceMFMilena De Felice
- Minyeong KimMKMinyeong Kim
- Seung-Hoon BaekSeung-Hoon Baek
- Ali AliAAAli Ali
- Jessica RedgraveJRJessica Redgrave
- Thorsten R. DoeppnerThorsten R. Doeppner
- Iain GardnerIGIain Gardner
- Ok-Nam BaeOBOk-Nam Bae
Open Access
- 26 April 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3053
Abstract
L-carnosine is an attractive therapeutic agent for acute ischemic stroke based on its robust preclinical cerebroprotective properties and wide therapeutic time window. However, large doses are needed for efficacy because carnosine is rapidly degraded in serum by carnosinases. The need for large doses could be particularly problematic when translating to human studies, as humans have much higher levels of serum carnosinases. We hypothesized that d-carnosine, which is not a substrate for carnosinases, may have a better pharmacological profile and may be more efficacious at lower doses than l-carnosine. To test our hypothesis, we explored the comparative pharmacokinetics and neuroprotective properties of d- and L-carnosine in acute ischaemic stroke in mice. We initially investigated the pharmacokinetics of d- and L-carnosine in serum and brain after intravenous (IV) injection in mice. We then investigated the comparative efficacy of d- and l-carnosine in a mouse model of transient focal cerebral ischemia followed by in vitro testing against excitotoxicity and free radical generation using primary neuronal cultures. The pharmacokinetics of d- and l-carnosine were similar in serum and brain after IV injection in mice. Both d- and l-carnosine exhibited similar efficacy against mouse focal cerebral ischemia. In vitro studies in neurons showed protection against excitotoxicity and the accumulation of free radicals. d- and l-carnosine exhibit similar pharmacokinetics and have similar efficacy against experimental stroke in mice. Since humans have far higher levels of carnosinases, d-carnosine may have more favorable pharmacokinetics in future human studies.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2017R1C1B3002626)
- Medical Research Council (MR/R005923/1)
This publication has 46 references indexed in Scilit:
- Serotonin Selective Reuptake Inhibitors (SSRIs) and StrokeCurrent Neurology and Neuroscience Reports, 2018
- Stroke: The past, present and futureBrain and Neuroscience Advances, 2018
- Heart Disease and Stroke Statistics—2015 UpdateCirculation, 2015
- Physiology and Pathophysiology of CarnosinePhysiological Reviews, 2013
- Caspase InhibitorsThe Neuroscientist, 2012
- New Approaches to Neuroprotective Drug DevelopmentStroke, 2011
- NXY-059Stroke, 2006
- C-EPO: Ready for Prime-Time Preconditioning?Cerebrovascular Diseases, 2005
- Neuroprotection for ischemic stroke: Two decades of success and failureNeuroRX, 2004
- Mechanisms, challenges and opportunities in strokeNature Reviews Neuroscience, 2003